TB-500 (Thymosin Beta-4): Tissue Repair Peptide Guide
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-31
How TB-500 promotes healing through actin regulation and angiogenesis
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide that regulates actin — the protein responsible for cell movement and tissue repair. It's used to accelerate healing of injuries, reduce inflammation, and promote angiogenesis.
TB-500 (Thymosin Beta-4, or Tβ4) is a 43-amino-acid peptide naturally produced in almost every cell and tissue in the body, with the highest concentrations at sites of injury. It plays a fundamental role in tissue repair by regulating actin — the structural protein that enables cells to move, which is essential for wound healing, inflammation response, and new blood vessel formation (angiogenesis).
In sports and biohacking communities, TB-500 is primarily used for injury recovery — particularly for tendons, ligaments, and muscle tears that respond slowly to conventional rehabilitation. It's often stacked with BPC-157 in the "wolverine stack," with the rationale that BPC-157 targets local repair signaling while TB-500 promotes the systemic vascular support (angiogenesis) needed to deliver repair cells to injury sites. TB-500 is one of the most-used healing peptides in peptide therapy.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →TB-500 Benefits
- Angiogenesis: TB-500 promotes formation of new blood vessels through upregulation of vascular endothelial growth factor (VEGF) and other angiogenic factors. This improves blood supply to injured tissues, which is rate-limiting for healing in avascular structures like tendons.
- Fibroblast migration: Regulates actin in fibroblasts (the cells that produce collagen), enabling them to migrate to injury sites and accelerate tissue remodeling.
- Anti-inflammatory: Reduces inflammatory cytokines at injury sites while preserving immune function needed for repair.
- Muscle healing: Multiple animal studies show accelerated repair of muscle injuries with reduced fibrosis and better functional recovery.
- Cardiac protection: Research in cardiac injury models shows TB-500 promotes cardiomyocyte survival and angiogenesis — an area of active pharmaceutical research.
- Hair growth: Some evidence for TB-500 promoting hair follicle stem cell activation, though this is not a primary clinical use.
TB-500 Dosage (Research Reference)
Standard TB-500 protocols from research and clinical contexts:
- Loading phase: 2–2.5 mg twice weekly × 4–6 weeks (for active injury)
- Maintenance phase: 2–2.5 mg once weekly or every 2 weeks
- Administration: Subcutaneous injection, TB-500 distributes systemically (unlike BPC-157 which is more effective locally injected)
- Wolverine stack: TB-500 2 mg 2x/week + BPC-157 250–350 mcg daily for 4–6 weeks during active injury; TB-500 2 mg weekly + BPC-157 250 mcg daily for ongoing maintenance
TB-500 vs BPC-157: Key Differences
| Factor | TB-500 | BPC-157 |
|---|---|---|
| Primary mechanism | Actin regulation, angiogenesis | Growth factor receptor upregulation, NO modulation |
| Distribution | Systemic (distributes broadly) | Works best near injury site when injected locally |
| Half-life | Longer (suitable for less frequent dosing) | Shorter |
| Best for | Systemic support, vascular supply, muscle | Tendon, gut, nerve, local tissue repair |
| FDA status (2026) | Research chemical; July 2026 PCAC vote recommended compounding access | Added to difficult-to-compound list (2024); July 2026 PCAC vote recommended return to compounding — FDA final decision pending |
| Typical dose | 2–2.5 mg 2x/week (loading) | 250–350 mcg daily |
TB-500 Side Effects and Safety
TB-500 has a favorable safety profile in the animal research literature, but human safety data is limited to community reporting rather than controlled trials. Commonly reported effects include mild injection-site redness or swelling, temporary fatigue or lethargy in the first few days of a cycle, and headache. These are generally self-limiting and resolve as the body adjusts.
Because TB-500 is not FDA-approved for human use and sold only as a research chemical, product quality varies significantly by vendor — impurities and inaccurate dosing are the more realistic safety concern than the peptide's own pharmacology at research-reference doses. Third-party lab testing (certificate of analysis) is the main way to reduce this risk.
TB-500 is prohibited in competitive sport by the World Anti-Doping Agency (WADA), the same status as most growth-factor and tissue-repair peptides. There is no well-established, publicly validated detection window for TB-500 the way there is for anabolic steroids — competitive athletes should treat it as detectable and prohibited rather than timing use around an assumed clearance period.
Frequently Asked Questions
What is TB-500?
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide present in virtually every cell and tissue. It promotes tissue repair by regulating actin (which enables cell movement), promoting angiogenesis (new blood vessel formation), and supporting fibroblast migration to injury sites.
What is the difference between BPC-157 and TB-500?
BPC-157 and TB-500 work through different mechanisms. BPC-157 primarily upregulates growth hormone receptors locally and modulates nitric oxide, working best when injected near the injury site. TB-500 regulates actin and promotes systemic angiogenesis, distributing throughout the body from any injection site. They're frequently combined in the 'wolverine stack' because they address complementary aspects of tissue repair.
What is TB-500 (TB 500) used for?
TB-500 is used primarily for accelerating recovery from tendon, ligament, and muscle injuries — especially those that respond slowly to conventional rehabilitation. Secondary uses include cardiac tissue protection (in research), anti-inflammatory effects, and potentially hair growth promotion.
Is TB-500 legal?
TB-500 is not FDA-approved for human therapeutic use — it is sold as a research chemical, which is the status shown in the FDA status row above. In July 2026, the FDA Pharmacy Compounding Advisory Committee reviewed TB-500 and recommended it be made eligible for compounding by licensed pharmacies — the FDA's final decision is still pending. Until that decision, TB-500 remains available primarily as a research chemical rather than a prescribed medication. Research-chemical legal status can vary by state, so check local regulations rather than assuming federal status applies everywhere.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Reading
-
BPC-157 vs TB-500: Tissue Repair Peptides Compared
BPC-157 vs TB-500: differences, use cases, and how to stack.